Browse by author
Lookup NU author(s): Dr Julien Peltier
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2018 The Author(s). Background: Colorectal cancer (CRC) remains a major cause of cancer fatalities in developed countries. The risk of death is correlated to the stage of CRC during the primary diagnosis. Early diagnosis is closely associated with enhanced survival rate. We therefore investigated the AP-F13A1 as a potential protein marker of CRC. Methods: The protein expression of FXIII in 40 serum samples was evaluated by enzyme-linked immunosorbent assays. Additionally, targeted proteomic assays (LC-PRM) were used to evaluate the expression of the activation peptide of F13A1 (AP-F13A1) in a further 113 serum samples. Results were analyzed by the Wilcoxon test and receiver operating characteristic curves generated to assess statistical differences and diagnostic factors between CRC patients and controls. Results: AP-F13A1 was quantified in human serum samples using calibration curves with excellent linearity. AP-F13A1 was reduced in CRC patients using PRM assays from two distinct biobanks. The AUC for AP-F13A1 were 0.95 and 0.93. Sensitivity/specificity values for the two sets of patients were 75%/95% and 71%/95% respectively. Conclusion: We have presented the proof of principle that in vivo release of AP-F13A1 can be measured by PRM-based strategies in CRC serum samples. AP-F13A1 may be an effective serological biomarker as part of a screening program of CRC detection.
Author(s): Peltier J, Roperch J-P, Audebert S, Borg J-P, Camoin L
Publication type: Article
Publication status: Published
Journal: Clinical Proteomics
Year: 2018
Volume: 15
Issue: 1
Online publication date: 09/04/2018
Acceptance date: 02/04/2018
Date deposited: 31/05/2018
ISSN (print): 1542-6416
ISSN (electronic): 1559-0275
Publisher: BioMed Central Ltd
URL: https://doi.org/10.1186/s12014-018-9191-3
DOI: 10.1186/s12014-018-9191-3
Altmetrics provided by Altmetric
